Patch clamp electrophysiology of VSM cells 25
VSM cells were acutely isolated from descending aorta as described (1) . K ATP currents were 26 recorded in whole-cell mode using an Axopatch 200B amplifier and Digidata 1322A (Molecular 27 Devices). Data were sampled at 3 kHz and low-pass filtered at 1 kHz. Cells were voltage-28 clamped at -70 mV and currents were initially recorded in a high Na + bath solution containing (in 29 mM): 136 NaCl, 6 KCl, 2 CaCl 2 , 1 MgCl 2 , 10 HEPES, and 10 glucose (pH 7.4) before exchange 30 with a high-K + bath solution (140 KCl, 2 CaCl 2 , 1 MgCl 2 , 10 HEPES, and 10 glucose, pH 7.4). 31
Pinacidil and glibenclamide were then administered as indicated. The pipette solution contained 32 (in mM) 110 potassium aspartate, 30 KCl, 10 NaCl, 1 MgCl 2 , 10 HEPES, 0.5 CaCl 2 , 4 K 2 HPO 4 , 33 and 5 EGTA (pH 7.2). K ATP current density was calculated by dividing whole cell currents in 34 pinacidil by cell capacitance. 35
36
Blood pressure measurements 37 Adult mice (3 months old) were anesthetized using 1.5% isoflurane and body temperature was 38 maintained with a heating pad throughout recordings. BPs were recorded following 39 catheterization of the left carotid artery with a Millar pressure transducer advanced to the 40 ascending aorta. Data were acquired using the Powerlab data acquisition system 41 (ADInstruments), and MAP was analyzed using LabChart 7 (ADInstruments). 42 43
Heart weight measurements 44
Adult (3 months old) mice were euthanized using 2.5% Avertin (Tribromoethanol). Hearts were 45 removed, rinsed in 10 % KCl solution and blotted to remove excess liquid and weighed. Heart 46 weight was normalized to tibia length (HW/TL; mg/mm). Echocardiography was performed using a Vevo 2100 Imaging System (VisualSonics) equipped 60 with a 30-MHz linear-array transducer according to previously published methods (4, 5). Cardiac 61 images were obtained by a handheld technique using 100 mg/kg i.p. tribromoethanol anesthetic; 62 aortic images were obtained under 1.5% inhaled isoflurane. Quantitative image analysis was 63 performed using a speckle-tracking algorithm to obtain volumetric data. Cardiac index was 64 calculated by normalizing cardiac output (stroke volume x heart rate) by tibia length. Systemic 65 vascular resistance was calculated from mice (> 20 g) by dividing mean arterial pressure 66 (determined from catheter measurements from anesthetized mice) by cardiac output (in turn 67 calculated from stroke volume measurements from echocardiographic data multiplied by heart 68 rate measurements from blood pressure recordings). Mice administered with both moderate-69 and high-dose pellets were grouped together as glibenclamide-treated mice for SVR and 70 cardiac index measurements. 71
Histology 73
Hearts were fixed in 10% buffered formalin (24 h), and embedded in paraffin. Sections (3 μm) 74
were cut and Gomori stained as previously reported(6). Left ventricle free-wall sections were 75 imaged from placebo and high-dose glibenclamide treated WT and SUR2 wt/AV mice (n of 3 for 76 each group). No differences in collagen staining between any group were observed. 37°C. An inverted microscope connected to a charged-coupled device camera and a 85 computerized system was used to visualize the artery and continuously record its 86 diameter. As intravascular pressure was increased from 0 to 175 mm Hg by 25 mmHg 87 increments, the vessel outer diameter was recorded at each step (12 seconds per step). 88 The average of three measurements at each pressure was reported. 89 90 91
Blood Glucose measurement in mice 92
Blood glucose (BG) was measured from tail-bleed samples using a digital blood glucose meter 93 (Contour). BG was measured in fed mice (food available ad libitum) prior to pellet implantation 94 and then periodically over 18 days post-implantation. To assess fasted blood glucose and for 95 glucose-tolerance tests (GTT), food was removed overnight (for ~ 10h) and BG measured the 96 following morning. GTT was performed by measuring blood glucose from tail bleed samples 97 immediately prior to administration of 1.5 g/kg D-glucose (in PBS), injected I.P. 98 99 LC-MS/MS analysis of plasma glibenclamide concentrations 100 60μl of mouse plasma was spiked with d11 glibenclamideand diluted to 1ml with 2% acetonitrile, 101 0.1 % formic acid prior to solid phase extraction. Eluted samples were evaporated, re-supended 102 in ammonium formate buffer and then subjected LC-MS/MS analysis using an ion trap mass 103 spectrometer following the method described by Lahmann et al. (7) . Six experimental replicates 104 were performed and concentrations were determined with reference to a glibenclamide standard 105 curve. 106
Preparation of glibenclamide standards: For the glibenclamide calibration standards, a stock 107 solution of glibenclamide (Santa Cruz Biotechnology) was dissolved in methanol (1mg/ml). 108
Mouse plasma was spiked with the stock glibenclamide solution, and using serial dilutions the 109 following standards were prepared: no drug, 1 ng/ml, 5 ng/ml, 10 ng/ml, 20 ng/ml, 30 ng/ml, 40 110 ng/ml, 50 ng/ml, 100 ng/ml 150 ng/ml. Quality control (QC) samples were also prepared at 50 111 ng/ml . Deuterated glibenclamide (d11-glibenclamide, Santa Cruz Biotechnology) was used as 112 the internal standard, and was added at a concentration of 333 ng/ml into all the calibration, QC 113 and study samples. 114
Study sample preparation and extraction: Study plasma samples (8 from low-dose and 8 from 115 high-dose pellet-implanted mice) were thawed and centrifuged at 14,000 x g for 10 minutes prior 116 to use, and 60μl was added to 20μl of internal standard (at 1μg/ml) and acidified with 80μl of 4% 117 orthophosphoric acid (from 85% w/w stock). The samples were then diluted by adding 800 μl of 118 buffer A (2% ACN, 0.1% FA), processed by reverse phase solid phase extraction (C18-SPE, 119
